Business Context and Reporting Period
Company: AspenBio Pharma, Inc. (Note: Request metadata listed "Riot Platforms," but the filing text is for AspenBio Pharma, a biopharmaceutical company).
Reporting Period: Quarterly report (Form 10-Q) for the three months ended March 31, 2008.
Business Overview: The company focuses on the development of diagnostic and therapeutic products, including an appendicitis blood test (AppyScore) and single-chain bovine products (BoviPure LH and FSH). The company is a non-accelerated filer and is not a shell company.
Key Financial Metrics
| Metric | Q1 2008 | Q1 2007 |
|---|---|---|
| Sales | $375,659 | $336,037 |
| Gross Profit | $160,723 | $165,643 |
| Gross Margin | 43% | 49% |
| Operating Loss | $(1,890,125) | $(854,781) |
| Net Loss | $(1,636,288) | $(868,364) |
| Loss Per Share (Basic/Diluted) | $(0.05) | $(0.04) |
| Cash and Cash Equivalents (End of Period) | $1,459,734 | $6,687,285 |
| Short-term Investments | $22,739,370 | $0 |
| Total Assets | $30,274,442 | $31,661,972 |
| Total Liabilities | $4,521,136 | $5,158,294 |
| Working Capital | $23,487,886 | $24,589,680 |
Cash Flow Summary (Q1 2008):
- Net cash used in operating activities: $(16,017,501) (Driven primarily by a $14.25M increase in short-term investments).
- Net cash used in investing activities: $(323,930).
- Net cash provided by financing activities: $424,408 (Primarily from option exercises).
Material Changes vs. Prior Period
- Revenue: Sales increased 12% to $376,000, driven by higher antigen sales. However, gross margin declined from 49% to 43% due to product mix changes.
- Operating Expenses: Total operating expenses surged 101% to $2.05M.
- Selling, General & Administrative (SG&A): Increased 73% to $1.25M due to higher public company costs, personnel hiring, and a $91,000 increase in stock-based compensation.
- Research & Development (R&D): Increased 171% to $798,000, primarily due to development costs for the appendicitis test ($328,000 increase) and single-chain products.
- Other Income: Interest income increased significantly by $223,000 to $269,000 due to higher investment balances following a late 2007 offering.
- Liquidity: Cash and cash equivalents decreased by approximately $15.9M, largely because the company deployed cash into short-term investments ($22.7M balance at quarter-end).
Guidance, Outlook, and Risks
- Novartis Agreement: In April 2008 (subsequent to period end), the company signed an exclusive license with Novartis Animal Health for BoviPure products. The deal includes a $2.0M upfront payment (50% non-refundable) and shared development costs. The company expects to fund 35% of development costs.
- Stock Repurchase: The board authorized a $5.0M stock repurchase plan. As of the filing date, approximately 232,000 shares had been repurchased for ~$992,000.
- Capital Needs: Management anticipates significant increases in R&D expenditures for the remainder of 2008 to support FDA 510(k) clearance for AppyScore and other pipeline products. Capital expenditures are estimated at $300,000–$500,000.
- Risks: The company expects to continue incurring cash losses. Revenue is concentrated; two customers accounted for 81% of sales in Q1 2008. Success depends on securing FDA approvals and commercializing products.
Investor Verification Checklist
- Novartis Deal Terms: Verify the conditions attached to the remaining 50% of the $2.0M upfront payment and the specific cost-sharing obligations.
- Customer Concentration: Assess the risk associated with two customers representing 81% of sales and 84% of accounts receivable.
- Debt Maturity: Review the $407,678 related-party note payable, which requires the remaining balance to be paid in full in June 2008.
- Investment Liquidity: Confirm the nature and liquidity of the $22.7M in short-term investments to ensure they can be liquidated to fund operations if needed.
- Stock-Based Compensation: Monitor the $2.04M in unrecognized compensation costs that will impact future earnings over the next three years.